CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ILYA PHARMA AB is developing ILP100 Topical, a biologic treatment for chronic wounds, particularly in diabetic patients. The project aims to demonstrate clinical proof of concept through exploratory trials, addressing significant healthcare challenges like antibiotic resistance and the socio-economic burden of non-heal…
ILYA PHARMA AB is a Swedish spin-out biotech company from Uppsala that develops next-generation biologics to treat wounds in skin and mucosa.In the previous SME Instrument project, the Company reached the First in Human (FiH) Phase I
clinical trial in the development of their technology platform (ILP) that utilizes chemokines as therapeutic agents through local administration from genetically modified lactic acid bacteria.The WHILYAS-2 project addresses several critical
problems and unmet medica…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
